Close Menu

NEW YORK ─ Pure-play in vitro diagnostics firm Ortho Clinical Diagnostics on Monday filed with the US Securities and Exchange Commission to go public on the Nasdaq.

Ortho did not price the offering but said in its Form S-1 that it intends to use the net proceeds from the offering to redeem $160.0 million in aggregate principal amount of 2025 notes; $270.0 million in aggregate principal amount of 2028 notes; and repay an undisclosed aggregate principal amount of borrowings under a dollar term loan facility.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Mar
18
Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Mar
29
Sponsored by
Thermo Fisher Scientific

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.